Dr. Wierda on RESONATE-2 Trial Predictions for Patients With CLL

William G. Wierda, MD, PhD
Published: Friday, Mar 20, 2015



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

RESONATE-2 is a phase III, randomized, multicenter, open-label study of elderly patients with CLL or SLL comparing ibrutinib to chlorambucil. In initial reports, Wierda expects results to demonstrate improved progression-free survival outcomes in patients receiving ibrutinib in the frontline setting. He predicts toxicity and tolerability will also improve.

It may be quite some time before overall survival differences are demonstrated, because patients can be salvaged with ibrutinib following chlorambucil, Wierda says.

This is based on findings in the RESONATE trial and similar single-arm trials with ibrutinib.


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

RESONATE-2 is a phase III, randomized, multicenter, open-label study of elderly patients with CLL or SLL comparing ibrutinib to chlorambucil. In initial reports, Wierda expects results to demonstrate improved progression-free survival outcomes in patients receiving ibrutinib in the frontline setting. He predicts toxicity and tolerability will also improve.

It may be quite some time before overall survival differences are demonstrated, because patients can be salvaged with ibrutinib following chlorambucil, Wierda says.

This is based on findings in the RESONATE trial and similar single-arm trials with ibrutinib.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x